» Articles » PMID: 17686054

Constitutive Fms-like Tyrosine Kinase 3 Activation Results in Specific Changes in Gene Expression in Myeloid Leukaemic Cells

Overview
Journal Br J Haematol
Specialty Hematology
Date 2007 Aug 10
PMID 17686054
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Constitutively activating internal tandem duplication (ITD) mutations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) play an important role in leukaemogenesis. We have examined, by cDNA microarray analysis, the changes in gene expression induced by FLT3/ITD or constitutively activated wild type FLT3 signalling. A limited set of genes was consistently affected by FLT3 inhibition. In confirmation of their FLT3 dependence, these genes returned toward pretreatment levels of expression after reversal of FLT3 inhibition. Several of the most significantly affected genes are involved in the RAS/mitogen-activated protein kinase, Janus kinase/signal transducer and activator of transcription and phosphatidylinositol 3 kinase (PI3K)/AKT pathways. These data suggest that constitutively activated FLT3 works through multiple signal transduction pathways. PIM1, MYC and CCND3 were chosen from this gene set to explore their biological roles. Knock-down of these genes by small interfering RNA showed that these genes play important roles in constitutively activated FLT3 expressing cells. The alterations of the gene expression profiles in these cells help to further elucidate the mechanisms of FLT3-mediated leukaemogenesis.

Citing Articles

Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.

Lee J, Chatterjee A, Scarpa M, Bailey C, Niyongere S, Singh P Cancer Res Commun. 2024; 4(2):431-445.

PMID: 38284896 PMC: 10870818. DOI: 10.1158/2767-9764.CRC-23-0379.


A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.

Long J, Chen X, Shen Y, Lei Y, Mu L, Wang Z Cell Rep Med. 2023; 4(11):101286.

PMID: 37951217 PMC: 10694671. DOI: 10.1016/j.xcrm.2023.101286.


Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-]pyridazine Derivatives Identified by Scaffold Hopping.

Brehova P, Reznickova E, Skach K, Jorda R, Dejmek M, Vojackova V J Med Chem. 2023; 66(16):11133-11157.

PMID: 37535845 PMC: 10461230. DOI: 10.1021/acs.jmedchem.3c00575.


Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.

Yashar W, Curtiss B, Coleman D, VanCampen J, Kong G, Macaraeg J Mol Cancer Res. 2023; 21(7):631-647.

PMID: 36976323 PMC: 10330306. DOI: 10.1158/1541-7786.MCR-22-0745.


PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.

Goswami S, Mani R, Nunes J, Chiang C, Zapolnik K, Hu E Blood. 2021; 139(9):1340-1358.

PMID: 34788382 PMC: 8900275. DOI: 10.1182/blood.2020010344.